Stem cell therapy for infertile women with diminished ovarian reserve (DOR)

Set up of new stem cell therapy method for infertile women with diminished ovarian reserve (DOR) by using autologous menstrual blood-derived stem cells and plasma rich platelet (PRP)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231230060569N1

Enrollment

Registered

2024-04-01

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished Ovarian Reserve(DOR). Ovarian dysfunction, unspecified

Interventions

Intervention 1: Intervention group: Injection of 1 ml of autologous PRP in 1 step into the ovaries of DOR patients under mild anesthesia with ultrasound guidance. Intervention 2: Intervention group:

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Female 20 to 45 years old with DOR having a history of infertility for more than a year Rejecting IVF at least once The total number of antral follicles is less than 7 in two ovaries or the serum level of Anti Müllerin hormone is less than 1.1 ng/ml. Having a low egg count or low-quality embryos in an IVF cycle Absence of ovulation or amenorrhea that did not occur for at least three months before entering the study.

Exclusion criteria

Exclusion criteria: Pregnant people IgA deficiency (before or now) Secondary ovarian failure caused by sex chromosomes. Taking anticoagulants History of mental illnesses with drug addiction Surgery leading to pelvic adhesions. Malignancy or chronic pelvic pain Infertility caused by strong male factor. Dissatisfaction with the intervention Abnormal uterine shape and endometrium caused by abscess.

Design outcomes

Primary

Measure	Time frame
Anti Mullerian hormone. Timepoint: 2 weeks before and after injection. Method of measurement: ELISA KIT.;Antral Follicle Count(AFC). Timepoint: 2 weeks before and after injection. Method of measurement: ELISA KIT.;Estradiol. Timepoint: 2 weeks before and after injection. Method of measurement: ELISA KIT.;FSH. Timepoint: 2 weeks before and after injection. Method of measurement: ELISA KIT.	—

Secondary

Measure	Time frame
Pregnancy success rate. Timepoint: after delivery. Method of measurement: Observation.;Embryo quality. Timepoint: 3 days after conception. Method of measurement: Microscope.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManizheh Habibpour

Mazandaran University of Medical Sciences

manizheh.habibpour@yahoo.com+98 11 3334 2905

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026